Orion Oyj Class A · OMXHEX:ORNAV
Orion Oyj Class A — Q3 2026 Earnings Presentation
20 slides from Orion Oyj Class A's earnings presentation, Oct 28, 2026
Slide 1: Orion Interim Report January-September 2026
Orion Interim Report January- September 2026 28 October 2026
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Q3 2026 Highlights
Q3 2026 Highlights • Strong net sales growth and improved profitability • Nubeqa® continued as the main growth driver • Broad-based growth across Branded Products • First large-molecule asset ODM-216 advanced into clinical development, marking an important R&D milestone • Interim results from DASL-H
Slide 4: Q3 2026 Financial highlights
Q3 2026 Financial highlights Net sales, EUR million Operating profit, EUR million Earnings per share, EUR Operating profit margin 38.7% (28.6%) +28.1% +73.5% +74.4% 542,2 209,9 1,19 423,2 121,0 0,68 Q3/2025 Q3/2026 Q3/2025 Q3/2026 Q3/2025 Q3/2026 28 October 2026
Slide 5: Net sales bridge (MEUR)
Net sales bridge (MEUR) 542.2 7.4 -4.6 -0.1 4.3 -0.5 112,5 423.2 Q3/2025 Innovative Branded Products Generics and Animal Health Fermion Translation Q3/2026 Medicines Consumer Health differences and other operations 28 October 2026 The figures in the chart are rounded, which is why the total sums of
Slide 6: Operating profit bridge (MEUR)
Operating profit bridge (MEUR) -0.1 -0.1 -22.3 209.9 103.8 121.0 2.6 4.9 Q3/2025 Changes in Changes in prices, Royalties Milestones Other operating Fixed costs Q3/2026 sales volume COGS, product income and mix and FX expenses 28 October 2026 The figures in the chart are rounded, which is why the tot
Slide 7: January-September 2026 Financial highlights
January-September 2026 Financial highlights Net sales, EUR million Operating profit, EUR million Earnings per share, EUR Operating profit margin 33.8% (25.4%) +24.1% +65.2% +65.9% 1,481.5 501,2 2,83 1,194.2 303,5 1,71 1–9/25 1–9/26 1–9/25 1–9/26 1–9/25 1–9/26 28 October 2026
Slide 8: Innovative Medicines
Innovative Medicines +62.5% Nubeqa® sales (MEUR) +65.7% 675.6 283.6 280 13.9 3.7 237 58 213 64 415.6 48 171.1 166 18.4 152 145 5.5 140 36 48 279,9 661,7 50 NET SALES MEUR NET SALES MEUR 44 222 95 92 72 26 165 173 165,6 397,2 38 50 21 116 118 18 96 95 69 54 51 32 2024 2024 2024 2024 2025 2025 2025 20
Slide 9: Branded Products
Branded Products • Growth across therapy areas +10.8% +10.1% 76.2 249.1 • Strong demand and good 68.7 9.9 226.1 32.1 product availability supported 6.8 21.8 Women’s Health growth 21.9 73.6 • Good momentum continued 19.8 71.4 across the Easyhaler® product portfolio NET SALES MEUR NET SALES MEUR • CNS
Slide 10: Generics and Consumer Health
Generics and Consumer Health • Slight decline in generic -3.4% -1.0% 135.9 prescription drugs net sales while 131.3 402.5 398.7 consumer health products net 33.9 98.3 sales remained on previous year’s 34.0 100.2 level • License agreement with Qilu to commercialize intravenous (IV) pembrolizumab bios
Slide 11: Animal Health
Animal Health • Net sales on previous year’s level -0.3% -1.8% 33.5 33.4 105.5 103.6 NET SALES MEUR NET SALES MEUR Q3/2025 Q3/2026 1–9/25 1–9/26 28 October 2026
Slide 12: Fermion
Fermion • Net sales (external sales) of +31.6% +21.5% Fermion consist of contract active 17.8 54.6 pharmaceutical ingredient (API) manufacturing, contract 44.9 13.5 development of APIs, and contract manufacturing of pharmaceutical products • Growth due to increase in sales of NET SALES MEUR NET SALE
Slide 13: Top products and net sales split in 1-9/2026
TOP 10 products and net sales split in 1-9/2026 Product or product portfolio EUR million vs 1-9/2025 1. Nubeqa® (prostate cancer) 661.7 66.6% 4% 7% 2. Easyhaler® product portfolio (asthma, COPD) 138.3 6.6% 3. Entacapone products (Parkinson’s disease) 62.8 -2.6% 46% 4. Divina® series (menopausal symp
Slide 14: Orion Pharma's key clinical development pipeline
Orion Pharma’s key clinical development pipeline Invented by Developer(s) Trial/compound Indication Phase I Phase II Phase III ARASTEP (darolutamide) prostate cancer (BCR2) DASL-HiCaP (darolutamide) (Neo-)adjuvant prostate cancer OMAHA-003 (opevesostat) prostate cancer (later-line mCRPC3) OMAHA-004
Slide 15: External recognition of Orion's sustainability management
External recognition of Orion’s sustainability management Our sustainability agenda ESG assessments and ratings Provider Result MSCI ESG Ratings AA EcoVadis Silver* CDP Climate: B Water security: B ISS Corporate Prime Rating *) Link to EcoVadis Recognition Page 15 28 October 2026
Slide 16: Outlook for 2026
Outlook for 2026 (provided on 20 October 2026) Net sales EUR 2,070 million–EUR 2,140 million Operating profit EUR 730 million–EUR 790 million 28 October 2026
Slide 17: Changes in Orion Executive Team
Changes in Orion Executive Team
Slide 18: We are entering the next phase of strategy execution
We are entering the next phase of strategy execution STRENGTHEN & BUILD & INVEST ACCELERATE EXPAND Build and invest into Grow & maximize value Strengthen European & global commercial assets of global assets APAC market position and capabilities Inspired by our Nordic heritage, we strive to empower p
Slide 19: Orion Executive Team as of 1 January 2027
Orion Executive Team as of 1 January 2027 • New International Commercial Operations organisation • More consistent commercial execution and closer coordination across markets and channels Juhani Kankaanpää Liisa Hurme EVP Global Operations, Mikko Kemppainen René Lindell Niclas Lindstedt President an
Slide 20: Upcoming events
Upcoming events Financial Statement Release 2026 17/2/2027 AGM planned to be held 23/3/2027 Interim Report 1–3/2027 22/4/2027 Half-Year Financial Report 1–6/2027 20/7/2027 Interim Report 1–9/2027 27/10/2027 28 October 2026